(Q42695369)

English

Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes

scientific article published on 3 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

author name string

H Watada

2

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

M Murai

3

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

T Kagimura

4

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Y Gong

5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

S Patel

6

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

H-J Woerle

7

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

publication date

3 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

833-843

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Diabetes in Japan: a review of disease burden and approaches to treatment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Gliptins: a new class of oral hypoglycaemic agent

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12110

21 January 2018

Identifiers

10.1111/DOM.12110

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42695369&oldid=1965665681"